BioMarin Licenses Subcutaneous Fabry Enzyme

Company BioMarin; GC Biopharma; Hanmi Pharm Event Type Exclusive worldwide license (excluding Korea) Modality Long-acting recombinant enzyme replacement (subcutaneous) Asset HM15421/GC1134A Target Alpha-galactosidase A replacement (Gb3 clearance) Disease Area Fabry disease Summary On 29 October BioMarin signed an exclusive worldwide license, excluding Korea, for HM15421/GC1134A…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding
Samsung Biologics Moves Into Peptide Manufacturing
Boulevard Bio Launches with $65 Million
GSK Acquires a Preclinical Trispecific Myeloma TCE